JP2023503840A5 - - Google Patents
Info
- Publication number
- JP2023503840A5 JP2023503840A5 JP2022527933A JP2022527933A JP2023503840A5 JP 2023503840 A5 JP2023503840 A5 JP 2023503840A5 JP 2022527933 A JP2022527933 A JP 2022527933A JP 2022527933 A JP2022527933 A JP 2022527933A JP 2023503840 A5 JP2023503840 A5 JP 2023503840A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- decoy
- tegfr
- subset
- variants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935308P | 2019-11-14 | 2019-11-14 | |
| US62/935,308 | 2019-11-14 | ||
| PCT/US2020/060505 WO2021097278A1 (en) | 2019-11-14 | 2020-11-13 | Compositions and methods for immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503840A JP2023503840A (ja) | 2023-02-01 |
| JP2023503840A5 true JP2023503840A5 (https=) | 2023-11-20 |
| JP7819923B2 JP7819923B2 (ja) | 2026-02-25 |
Family
ID=75912441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527933A Active JP7819923B2 (ja) | 2019-11-14 | 2020-11-13 | 免疫療法のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387555A1 (https=) |
| EP (1) | EP4058035A4 (https=) |
| JP (1) | JP7819923B2 (https=) |
| KR (1) | KR20220101151A (https=) |
| CN (1) | CN115151267B (https=) |
| AU (1) | AU2020381514A1 (https=) |
| BR (1) | BR112022009303A2 (https=) |
| CA (1) | CA3157416A1 (https=) |
| IL (1) | IL292872A (https=) |
| MX (1) | MX2022005535A (https=) |
| WO (1) | WO2021097278A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4058035A4 (en) * | 2019-11-14 | 2023-12-27 | Ludwig Institute for Cancer Research Ltd | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
| US20240207319A1 (en) * | 2021-05-06 | 2024-06-27 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| WO2025133340A1 (en) | 2023-12-21 | 2025-06-26 | Ludwig Institute For Cancer Research Ltd | Heterodimeric proteins comprising dimerization motifs and methods of using |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7381405B2 (en) | 2002-10-15 | 2008-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer |
| CN101146823A (zh) * | 2005-02-15 | 2008-03-19 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| PT3177640T (pt) * | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| EP3217993A1 (en) * | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| CN106967684A (zh) | 2016-01-13 | 2017-07-21 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途 |
| CN109715205A (zh) * | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
| GB201620070D0 (en) | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| WO2018170390A1 (en) * | 2017-03-17 | 2018-09-20 | Senti Biosciences, Inc. | Immunomodulating cell circuits |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| CN108997492B (zh) * | 2018-07-19 | 2022-04-12 | 海珂分子（北京）科技有限责任公司 | 高亲和力的pd1胞外区突变体多肽及相关融合蛋白 |
| EP4058035A4 (en) * | 2019-11-14 | 2023-12-27 | Ludwig Institute for Cancer Research Ltd | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
| US20230414660A1 (en) | 2020-11-13 | 2023-12-28 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
-
2020
- 2020-11-13 EP EP20888482.5A patent/EP4058035A4/en active Pending
- 2020-11-13 AU AU2020381514A patent/AU2020381514A1/en active Pending
- 2020-11-13 MX MX2022005535A patent/MX2022005535A/es unknown
- 2020-11-13 CA CA3157416A patent/CA3157416A1/en active Pending
- 2020-11-13 JP JP2022527933A patent/JP7819923B2/ja active Active
- 2020-11-13 WO PCT/US2020/060505 patent/WO2021097278A1/en not_active Ceased
- 2020-11-13 US US17/776,650 patent/US20220387555A1/en active Pending
- 2020-11-13 KR KR1020227020028A patent/KR20220101151A/ko not_active Withdrawn
- 2020-11-13 CN CN202080090036.7A patent/CN115151267B/zh active Active
- 2020-11-13 BR BR112022009303A patent/BR112022009303A2/pt not_active Application Discontinuation
-
2022
- 2022-05-09 IL IL292872A patent/IL292872A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503840A5 (https=) | ||
| Castellarin et al. | Driving cars to the clinic for solid tumors | |
| AU2014225788B2 (en) | Engager cells for immunotherapy | |
| Liu et al. | Driving better and safer HER2-specific CARs for cancer therapy | |
| Yao et al. | Trispecific antibodies for cancer immunotherapy | |
| JP2019150066A5 (https=) | ||
| JP2018523485A5 (https=) | ||
| JP2021502810A5 (https=) | ||
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| WO2023020423A1 (en) | Ror1 car or ror1 /cd19 dual car t cells for the treatment of tumors | |
| JP2019535262A5 (https=) | ||
| JP2020516276A5 (https=) | ||
| JP2018529327A5 (https=) | ||
| JP2021512614A5 (https=) | ||
| CN109053899B (zh) | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 | |
| CN110035768A (zh) | 嵌合抗原受体 | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| US20230130737A1 (en) | Multifunctional Heteromultimeric Constructs | |
| JP2022553292A5 (https=) | ||
| JP2022548112A5 (https=) | ||
| CA3109635A1 (en) | Cell sorting systems and methods of use | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| CN118786142A (zh) | 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞 | |
| JP2023527621A5 (https=) |